Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive cancer showing a very poor prognosis because of metastasis formation at an early stage and acquisition of chemoresistance. One key driver of chemoresistance is the transcription factor Forkhead box protein M1 (FOXM1) that regulates cell cycle proliferat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Taromi, Sanaz, Lewens, Florentine, Arsenic, Ruza, Sedding, Dagmar, Sänger, Jörg, Kunze, Almut, Möbs, Markus, Benecke, Joana, Freitag, Helma, Christen, Friederike, Kaemmerer, Daniel, Lupp, Amelie, Heilmann, Mareike, Lammert, Hedwig, Schneider, Claus-Peter, Richter, Karen, Hummel, Michael, Siegmund, Britta, Burger, Meike, Briest, Franziska, Grabowski, Patricia
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5722545/
https://ncbi.nlm.nih.gov/pubmed/29228593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21221
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki